Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02YEG
|
||||
Former ID |
DIB006170
|
||||
Drug Name |
VBY-376
|
||||
Synonyms |
Protease inhibitor (hepatitis C virus infection), Virobay
|
||||
Indication | HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2] | Phase 1 | [1] | ||
Company |
Virobay Inc
|
||||
Target and Pathway | |||||
Target(s) | Nonstructural protein NS3 | Target Info | Inhibitor | [2] | |
References | |||||
REF 1 | ClinicalTrials.gov (NCT00557583) Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults. U.S. National Institutes of Health. | ||||
REF 2 | Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses. 2010 August; 2(8): 1752-1765. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.